申请人:Takeda Chemical Industries, Ltd.
公开号:EP1424336A1
公开(公告)日:2004-06-02
This invention provides a compound represented by the formula (I) :
wherein R1 is a hydrogen atom, a halogen atom, hydroxy, nitro, optionally halogenated alkyl, alkoxy optionally having substituents, acyl or amino optionally having substituents;
R2 is pyridyl, furyl, thienyl, pyrrolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, tetrahydroquinolyl or thiazolyl, each of which may have substituents;
n is 1 or 2; or a salt. And this invention provides a safe pharmaceutical comprising the compound of the formula (I) , which has an excellent apoptosis inhibitory effect and MIF binding effect, for preventing and/or treating heart disease, nervous degenerative disease, cerebrovascular disease, central nervous infectious disease, traumatorathy, demyelinating disease, bone and articular disease, kidney disease, liver disease, osteomyelodysplasia, AIDS, cancer, and the like.
这项发明提供了一种由以下式(I)表示的化合物:
其中R1是
氢原子、卤素原子、羟基、硝基、可选择具有卤素取代基的烷基、可选择具有取代基的烷
氧基、酰基或
氨基;
R2是
吡啶基、
呋喃基、
噻吩基、
吡咯基、
喹啉基、
吡嗪基、
嘧啶基、
吡啶并
嘧啶基、
吲哚基、
四氢喹啉基或
噻唑基,每种基团可能具有取代基;
n为1或2;或其盐。该发明提供了一种安全的药物,包括具有优异的凋亡抑制作用和MIF结合作用的式(I)化合物,用于预防和/或治疗心脏病、神经退行性疾病、脑血管疾病、中枢神经感染性疾病、创伤病变、
脱髓鞘疾病、骨骼和关节疾病、肾脏疾病、肝脏疾病、骨髓发育不良、艾滋病、癌症等。